Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Oprozomib |
| Synonyms | |
| Therapy Description |
Oprozomib (ONX 0912) is a proteasome inhibitor that inhibits CT-L proteosome activity, leading to induction of autophagy and apoptosis in tumor cells (PMID: 22929803, PMID: 31229804). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Oprozomib | ONX 0912|PR-047 | Oprozomib (ONX 0912) is a proteasome inhibitor that inhibits CT-L proteosome activity, leading to induction of autophagy and apoptosis in tumor cells (PMID: 22929803, PMID: 31229804). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02227914 | Phase Ib/II | Oprozomib Sorafenib | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | Withdrawn | USA | 0 |